Name (Synonyms) | Correlation | |
---|---|---|
drug2486 | The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: Wiki | 0.71 |
drug315 | Baricitinib Wiki | 0.27 |
Name (Synonyms) | Correlation | |
---|---|---|
D001997 | Bronchopulmonary Dysplasia NIH | 0.71 |
D008595 | Menorrhagia NIH | 0.71 |
D006929 | Hyperaldosteronism NIH | 0.71 |
D014552 | Urinary Tract Infections NIH | 0.71 |
D054559 | Hyperphosphatemia NIH | 0.71 |
D004314 | Down Syndrome NIH | 0.71 |
D000309 | Adrenal Insufficiency NIH | 0.71 |
D007008 | Hypokalemia NIH | 0.71 |
D009080 | Mucocutaneous Lymph Node Syndrome NIH | 0.50 |
D001289 | Attention Deficit Disorder with Hyperactivity NIH | 0.35 |
D020141 | Hemostatic Disorders NIH | 0.21 |
D001778 | Blood Coagulation Disorders NIH | 0.21 |
D006973 | Hypertension NIH | 0.20 |
D004194 | Disease NIH | 0.13 |
D013577 | Syndrome NIH | 0.08 |
D003141 | Communicable Diseases NIH | 0.06 |
D007239 | Infection NIH | 0.04 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002905 | Hyperphosphatemia HPO | 0.71 |
HP:0002900 | Hypokalemia HPO | 0.71 |
HP:0000846 | Adrenal insufficiency HPO | 0.71 |
HP:0000132 | Menorrhagia HPO | 0.71 |
HP:0000859 | Hyperaldosteronism HPO | 0.71 |
HP:0007018 | Attention deficit hyperactivity disorder HPO | 0.35 |
HP:0001928 | Abnormality of coagulation HPO | 0.21 |
HP:0000822 | Hypertension HPO | 0.20 |
There are 2 clinical trials
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
The main objectives are: - To establish the prevalence of major bleeding in patients treated with higher than recommended thromboprophylaxis doses. - To identify variables associated to higher risk of bleeding.
Description: Study endpoints are clinically recognized (and objectively confirmed) major and minor bleeding complications, and death.
Measure: Bleeding events and complications Time: 30 days